CEO and Founder of SCARLETRED, Dr. Harald Schnidar, attended BIO International Convention 2026. In San Diego, Dr. Schnidar connected with the global biotech and pharma leaders in dermatology, immunology, vaccines, and injectable therapies to explore how objective, standardized skin imaging can address one of the industry’s most underestimated challenges: “Many skin-focused drug programs do not have a molecule problem – they have a measurement problem,” says Dr. Schnidar.

Critical decisions in dermatology and skin-related drug development are still too often based on endpoints that are subjective, variable across sites, and difficult to compare over time.  

That creates noise exactly where sponsors need clarity: in detecting early treatment signals, generating late-stage evidence, and strengthening an asset for out-licensing and post-marketing.

The conversations in San Diego confirmed what SCARLETRED sees in global clinical studies: objective, AI-powered skin analysis is becoming a strategic requirement. SCARLETRED is ready to meet that demand.

Scarletred®Vision delivers the endpoint quality that modern drug development demands

As an AI-MedTech company and the worldwide leader in clinically validated, standardized skin imaging, SCARLETRED develops Scarletred®Vision – the certified Software as a Medical Device (SaMD) that transforms how skin is documented, assessed, and monitored. From inflammatory skin diseases to injection site reactions, Scarletred®Vision delivers endpoint quality that modern drug development demands.

BIO International Convention 2026 confirmed that sponsors across dermatology, immunology, and injectable therapies are actively seeking better measurement frameworks for clinical development, for regulatory submissions, and for commercial discussions around asset valuation and partnering.  

For more information on how SCARLETRED can support skin-focused drug programs, contact office@scarletred.com.

‍

‍